特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
824898

世界の重症筋無力症(MG)市場:産業予測

Global Myasthenia Gravis Market Research Report Forecast to 2023

出版日: | 発行: Market Research Future | ページ情報: 英文 175 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.64円
世界の重症筋無力症(MG)市場:産業予測
出版日: 2019年03月31日
発行: Market Research Future
ページ情報: 英文 175 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の重症筋無力症(MG)市場について調査分析を行い、市場概要、市場動向、市場促進因子/抑制因子などについて考察するとともに、種類別、診断/治療別、エンドユーザー別、地域別に市場を分析、主要企業のプロファイルなどについて包括的に分析し、まとめています。

第1章 エグゼクティブサマリー

第2章 市場のイントロダクション

第3章 調査方法

第4章 市場のダイナミクス

  • イントロダクション
  • 促進因子
  • 抑制因子
  • 機会
  • 市場動向
  • マクロ経済学的指標
  • 臨床試験データ

第5章 市場因子分析

  • ファイブフォース分析
  • サプライチェーン分析
  • 価格分析

第6章 世界の重症筋無力症(MG)市場:種類別

  • イントロダクション
  • 眼筋型重症筋無力症
  • 先天性重症筋無力症
  • 全身型重症筋無力症
  • 一過性重症筋無力症

第7章 世界の重症筋無力症(MG)市場:診断/治療別

  • 概要
  • 診断/治療
  • 診断
  • 治療

第8章 世界の重症筋無力症(MG)市場:エンドユーザー別

  • イントロダクション
  • 病院/クリニック
  • 診断センター
  • 学術/研究機関

第9章 世界の重症筋無力症(MG)市場:地域別

  • イントロダクション
  • 南北アメリカ
  • 欧州
  • アジア太平洋地域
  • 中東/アフリカ
  • 中東
  • アフリカ

第10章 競合状況

  • イントロダクション

第11章 企業プロファイル

  • Alexion Pharmaceuticals, Inc
  • GE Healthcare
  • Pfizer Inc.
  • Novartis AG
  • F. Hoffmann-La Roche AG
  • CSL Behring
  • Boston Scientific Corporation
  • Baxter
  • Grifols S.A.
  • Medtronic Plc
  • Koninklijke Philips N.V.
  • Shire
  • Valeant Pharmaceuticals International, Inc.

第12章 付録

目次

Myasthenia Gravis Market: By Type (Ocular Myasthenia Gravis, Congenital Myasthenia Gravis, Generalized Myasthenia Gravis, Transient Myasthenia Gravis, and Others), (Diagnosis and Treatment), End User (Hospitals and Clinics, Diagnostic Centers and Academic and Research Organizations) and By Region-Global Forecast Till 2023

Market analysis

Myasthenia gravis (MG) is an immune system neuromuscular illness, its essential effect incorporates a reduction in the convergence of AChRs on the muscle endplate membrane. North America and Latin America altogether make the biggest commitment to the development of the global myasthenia gravis market. In the meantime, Europe and the Asia Pacific hold the second and third spot regarding value. There has been a significant ascent in the predominance of myasthenia gravis as of late, which prompted a sharp increment in treatment request. The global myasthenia gravis market is anticipated to witness an annual growth rate of 9.61% during the estimated period (2018- 2023).

Market segmentation

The global myasthenia gravis market has been segmented on the basis of its type, diagnosis and treatment, end-user and regional demand. Based on its type, the global myasthenia gravis market is segmented as Congenital myasthenia gravis, Ocular myasthenia gravis, Transient myasthenia gravis, Generalized myasthenia gravis, Others. Based on its diagnosis, the market is bifurcated into Electrodiagnostic testing & imaging and Lab-based test. On the basis of its treatment, the global myasthenia gravis market is divided into Immunosuppressive drugs, Cholinesterase inhibitors, Thymectomy, Plasmapheresis, and intravenous immunoglobulin. Based on its end-user industry, the market is divided into Hospitals and Clinics, Academic and Research organizations, Diagnostic Centers.

Regional analysis

Geographically, the global myasthenia gravis market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major players

CSL Behring, Medtronic Plc., Baxter, Grifols S.A., Shire, Koninklijke Philips N.V., and Valeant Pharmaceuticals International, Inc, GE Healthcare, Alexion Pharmaceuticals, Inc, Novartis AG, Pfizer Inc., Boston Scientific Corporation, among others are some of the major players in the global myasthenia gravis market.

Table of Contents

1 Executive Summary

2 Market Introduction

  • 2.1 Definition
  • 2.2 Scope of the Study
  • 2.3 Assumptions & Limitations
    • 2.3.1 Assumptions
    • 2.3.2 Limitations
  • 2.4 Market Structure

3 Research Methodology

  • 3.1 Research Process
  • 3.2 Primary Research
  • 3.3 Secondary Research
  • 3.4 Market Size Estimation
  • 3.5 Forecast Model

4 Market Dynamics

  • 4.1 Introduction
  • 4.2 Drivers
    • 4.2.1 Rising Research Funding for Myasthenia Gravis
    • 4.2.2 Awareness Programs and Initiatives Taken by Associations
    • 4.2.3 Rising Prevalence of MG
  • 4.3 Restraints
    • 4.3.1 High Cost of Treatment Associated with Myasthenia Gravis
  • 4.4 Opportunities
    • 4.4.1 Strong pipeline
  • 4.5 Market Trends
  • 4.6 Macroeconomic Indicators
  • 4.7 Clinical Trials Data

5 Market Factor Analysis

  • 5.1 Porter's Five Forces Analysis
    • 5.1.1 Bargaining Power of Suppliers
    • 5.1.2 Bargaining Power of Buyers
    • 5.1.3 Threat of New Entrants
    • 5.1.4 Threat of Substitutes
    • 5.1.5 Intensity of Rivalry
  • 5.2 Supply Chain Analysis
    • 5.2.1 R&D
    • 5.2.2 Manufacturing
    • 5.2.3 Distribution
    • 5.2.4 Marketing & Sales
    • 5.2.5 Post-Sales Monitoring
  • 5.3 Pricing Analysis

6 Global Myasthenia Gravis Market, By Type

  • 6.1 Introduction
  • 6.2 Ocular Myasthenia Gravis
  • 6.3 Congenital Myasthenia Gravis
  • 6.4 Generalized Myasthenia Gravis
  • 6.5 Transient Myasthenia Gravis

7 Global Myasthenia Gravis Market, By Diagnosis & Treatment

  • 7.1 Introduction
  • 7.2 Diagnosis & Treatment
  • 7.3 Diagnosis
  • 7.4 Treatment

8 Global Myasthenia Gravis Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Diagnostic Centers
  • 8.4 Academic & Research Organizations

9 Global Myasthenia Gravis Market, By Region

  • 9.1 Introduction
  • 9.2 The Americas
    • 9.2.1 North America
      • 9.2.1.1 U.S
      • 9.2.1.2 Canada
    • 9.2.2 South America
  • 9.3 Europe
    • 9.3.1 Western Europe
      • 9.3.1.1 Germany
      • 9.3.1.2 France
      • 9.3.1.3 UK
      • 9.3.1.4 Italy
      • 9.3.1.5 Spain
      • 9.3.1.6 Rest of Western Europe
      • 9.3.1.7 Eastern Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 JAPAN
    • 9.4.3 Australia
    • 9.4.4 INDIA
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 The Middle East & Africa
  • 9.6 Middle East
  • 9.7 AFRICA

10 Competitive Landscape

  • 10.1 Introduction

11 Company Profile

  • 11.1 Alexion Pharmaceuticals, Inc
    • 11.1.1 Company Overview
    • 11.1.2 Financial Overview
    • 11.1.3 Products/Services Offered
    • 11.1.4 Key Developments
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Strategy
  • 11.2 GE Healthcare
    • 11.2.1 Company Overview
    • 11.2.2 Financial Overview
    • 11.2.3 Products/Services Offered
    • 11.2.4 Key Developments
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Strategy
  • 11.3 Pfizer Inc.
    • 11.3.1 Company Overview
    • 11.3.2 Financial Overview
    • 11.3.3 Products/Services Offering
    • 11.3.4 Key Developments
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Strategy
  • 11.4 Novartis AG
    • 11.4.1 Company Overview
    • 11.4.2 Products/Services Offered
    • 11.4.3 Key Developments
    • 11.4.4 SWOT Analysis
    • 11.4.5 Key Strategy
  • 11.5 F. Hoffmann-La Roche AG
    • 11.5.1 Company Overview
    • 11.5.2 Financial Overview
    • 11.5.3 Products/Services Offered
    • 11.5.4 Key Developments
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Strategy
  • 11.6 CSL Behring
    • 11.6.1 Financial Overview
    • 11.6.2 Products/Services Offered
    • 11.6.3 Key Developments
    • 11.6.4 SWOT Analysis
    • 11.6.5 Key Strategy
  • 11.7 Boston Scientific Corporation
    • 11.7.1 Company Overview
    • 11.7.2 Financial Overview
    • 11.7.3 Products/Services Offered
    • 11.7.4 Key Developments
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Strategy
  • 11.8 Baxter
    • 11.8.1 Company Overview
    • 11.8.2 Company Overview
    • 11.8.3 Products/Services Offered
    • 11.8.4 SWOT Analysis
    • 11.8.5 Key Developments
    • 11.8.6 Key strategy
  • 11.9 Grifols S.A.
    • 11.9.1 Company Overview
    • 11.9.2 Financial Overview
    • 11.9.3 Products/Services Offered
    • 11.9.4 Key Developments
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Strategy
  • 11.1 Medtronic Plc
    • 11.10.1 Company Overview
    • 11.10.2 Financial Overview
    • 11.10.3 Products/Services Offered
    • 11.10.4 Key Developments
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Strategy
  • 11.11 Koninklijke Philips N.V.
    • 11.11.1 Company Overview
    • 11.11.2 Financial Overview
    • 11.11.3 Products/Services Offered
    • 11.11.4 Key Developments
    • 11.11.5 SWOT Analysis
    • 11.11.6 Key Strategy
  • 11.12 Shire
    • 11.12.1 Company Overview
    • 11.12.2 Financial Overview
    • 11.12.3 Products/Services Offered
    • 11.12.4 Key Developments
    • 11.12.5 SWOT Analysis
    • 11.12.6 Key Strategy
  • 11.13 Valeant Pharmaceuticals International, Inc.
    • 11.13.1 Company Overview
    • 11.13.2 Financial Overview
    • 11.13.3 Products/Services Offered
    • 11.13.4 Key Developments
    • 11.13.5 SWOT Analysis
    • 11.13.6 Key Strategy

12 Appendix

  • 12.1 Discussion Blue Print
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.